Retatrutide from a lab vial: what independent testing found

Reviewed 10 sourcesPublished by PepVault

Two retatrutide samples matched a basic standard; a third held no peptide and 13 bacterial colonies. What the tests and UK seizures show, as of Nov 20, 2026.

A hand in a navy sleeve holds a crimp-sealed glass vial up to the light, basil and lemons behind
Last reviewed
Sources
10
Questions
7
Compounds
3

The short answer

In a lab test CBS News published on October 21, 2026, University of Iowa scientists checked three samples sold as retatrutide. Two matched a basic retatrutide standard; the third held no peptide, only a fragrance filler, plus 13 bacterial colonies. No one measured the matching samples' amount, purity or sterility. Retatrutide is approved nowhere, as of November 20, 2026.

Every number checked at its primary source · · 10 sources · How we research

Evidence: One lab test of three samples commissioned by CBS News (journalism, not peer-reviewed), UK regulator seizure notices with no content testing, one peer-reviewed test-purchase study of online semaglutide, and two case reports; dated as of November 20, 2026.

A hand in a navy sleeve holds a crimp-sealed glass vial up to the light, basil and lemons behind

What did the CBS News lab test of retatrutide find?

The most striking result came from the third sample. On October 21, 2026, CBS News published a lab test of three products sold as retatrutide, Eli Lilly's experimental weight-loss drug1. Jason Galpin, a research scientist at the University of Iowa, analyzed them. Two were ordered online. The third was a vial labeled "Retatrutide" and "Research use only, not for human consumption"1.

SampleWhat the lab foundNot reported
Sample 1Consistent with a basic retatrutide standard the scientist madeAmount, purity, bacteria, endotoxin
Sample 2Consistent with the same standardAmount, purity, bacteria, endotoxin
Sample 3, labeled "Research use only"No peptide: phenylacetic acid, a filler found in fragrances and lip balms; 13 bacterial coloniesAmount, endotoxin

Of sample 3, Galpin said: "It does not look anything like a peptide"1. Carl Ross of the university's Center for Biocatalysis and Bioprocessing grew 13 colonies of bacteria from it and called the finding "pretty terrifying", because injecting bacteria can cause an infection1. The article names no testing method and gives no percentage for any sample1.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's vial record has a batch note: type the lot number from the label there, and it stays with that vial's record.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What does "consistent with a standard" prove about a vial?

It proves identity, and only roughly. A standard is a reference sample the lab compares the unknown against. CBS states the limit in the same sentence as the result: the standard Galpin created "isn't the same as the drug being studied in Eli Lilly's clinical trials"1. So the two online samples looked like retatrutide. The test does not say how many milligrams each vial held, what share of the powder was the drug, whether it was sterile, or whether it carried endotoxin, the fever-causing debris of dead bacteria (pepvault.app/glossary/endotoxin).

Retatrutide is a large molecule, which makes identity the easy part. PubChem, the US National Library of Medicine's chemistry database, lists its formula as C221H342N46O68 and its molecular weight as 4,7317. A mass reading near that number says the right molecule is present. It cannot say whether a vial also holds broken chains, the wrong amount or microbes.

Peptide SkySee Retatrutide as a molecule53 peptides as a night sky in 3D. Each star opens into its molecule, one bead per amino acid, with the measured shape where one exists.Open the Peptide Sky

Lilly's statement to CBS made the same point about time: "A single test is a snapshot, not a guarantee that the dose will be sterile or stable in two weeks." It added that third-party testing of one sample of unknown origin "does not make an illegal product safe"1.

What did the UK seize in October 2026?

On October 14, 2026, the UK's medicines regulator, the MHRA, and West Midlands Police raided an industrial unit in Birmingham. They seized more than 12,000 fake retatrutide and tirzepatide pens and packaging for around 30,000 more products, worth about 2 million pounds. An MHRA official called the site a "filthy warehouse"2.

The notice, published October 15, reports no lab test of the pens. The MHRA says the products "have not been assessed for safety, quality or effectiveness" and that their contents, and any contamination, are unknown2. It was the latest in a run of seizures the same notice lists:

WhenWhat the MHRA reported
October 2025The first illicit weight-loss medicine factory found in the UK: 5,000 unauthorized retatrutide and tirzepatide pens, thousands of empty pens and raw ingredients
February 2026About 2,000 doses awaiting dispatch, with manufacturing equipment
May 2026About 12,000 doses at a country estate; two people arrested
October 14, 2026More than 12,000 fake retatrutide and tirzepatide pens, packaging for about 30,000 more

A pen matters here because it looks like a licensed product. Retatrutide has no licensed pen anywhere: in the MHRA's words, it "has not been authorised for use in the UK", and products sold as retatrutide outside legitimate clinical trials are supplied illegally2.

Have labs found the same problems in other online GLP-1s?

Yes, and the pattern shows why an identity match is not enough. Researchers at the University of Pécs in Hungary bought semaglutide from illegal online pharmacies in 2023 and tested the three vials that arrived6. Each held real semaglutide, 28.6% to 38.7% more than the label claimed. Yet the labels claimed 99% purity, and the measured purity ran from 7.7% to 14.4%6. No live microbes grew, but the lab reported endotoxin in every vial6.

Sterile and clean are two separate tests. PepVault's guide to reading a certificate of analysis (pepvault.app/guides/how-to-read-a-peptide-coa) walks through that study line by line, with a Belgian study of falsified peptide drugs beside it.

What can a COA show for a retatrutide vial, and what can't it?

A certificate of analysis (COA) is a lab's report on one batch, called a lot (pepvault.app/glossary/coa). Held against the tests above, it covers some of the gaps the CBS test left open and none of the gaps that matter most.

  • It can show a mass near 4,731 for identity7, a purity figure for that lot, and, if listed, endotoxin and sterility results for the samples tested.
  • It can't show that the vial in your hand came from that lot. Only the lot number printed on both links them, and that link is the label's word.
  • It can't show how the vial fared later. Lilly's "snapshot" point applies to every COA: a result describes its test date, not shipping, storage or the weeks after mixing1.
  • It can't show that the product is Lilly's drug. Every trial result for retatrutide belongs to Lilly's own product, which Lilly says "cannot be legally sold or marketed for human use"4.
  • It can't change the label's meaning. The FDA says products labeled "for research purposes" or "not for human consumption" have been sold directly to consumers for human use with dosing instructions, and that they are "of unknown quality and may be harmful"3.

PepVault's vial record has a batch note: type the lot number from the label there, and it stays with that vial's record. Track your vials in PepVault

Is retatrutide approved anywhere yet?

No, as of November 20, 2026. Lilly's October 28 release says it "has not been approved by FDA or any regulatory organization anywhere in the world"5, and on July 23, 2026, Lilly said it plans to file its Biologics License Application with the FDA in the first quarter of 20274. The FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, says retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition3.

Enforcement is uneven. Public Citizen, a consumer advocacy group, counted 14 FDA warning letters to companies selling retatrutide since 2024, and found in May 2026 that eight of those companies still sold it8. The status by country is on pepvault.app/peptides/retatrutide/legal-status, and the approval timeline in PepVault's guide on when retatrutide will be approved.

What should you do if you feel unwell after using a vial?

Tell the clinician exactly what you injected, and bring the vial and its label. Two 2026 case reports describe patients admitted with vomiting after injecting products sold as retatrutide, and both ask doctors to ask about peptides and online products, because they can slip past a routine medication history910. PepVault's guide on whether retatrutide is safe covers those cases and what the trials reported.

Reports are how regulators learn what a product does. In the UK, the MHRA asks anyone with a side effect to tell their doctor, pharmacist or nurse and report it through the Yellow Card scheme2. In the US, the FDA takes reports of side effects and quality problems through MedWatch3. Public Citizen counted 10 reports naming retatrutide in the FDA's adverse event system in 2025 and 26 in the first five months of 20268.

PepVault's side-effect log keeps each symptom with its date, the compound and a severity, and the doctor's report puts them beside your logged doses in one document. Log it in PepVault

When to get help Fever, chills, or redness and swelling spreading from an injection site, or vomiting that stops you keeping fluids down, is a reason to get medical care the same day.

Track it in the app

Sources

  1. Yamaguchi A, Geller L. We bought and tested what was sold as an experimental weight loss drug. The lab results were "pretty terrifying." CBS News, October 21, 2026. cbsnews.com
  2. Medicines and Healthcare products Regulatory Agency (MHRA). Counterfeit weight loss pens worth £2 million seized by MHRA and West Mids Police. GOV.UK, published October 15, 2026. gov.uk
  3. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. fda.gov
  4. Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials. Press release, July 23, 2026. prnewswire.com
  5. Eli Lilly and Company. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial. Press release, October 28, 2026. prnewswire.com
  6. Ashraf AR et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription: market surveillance, content analysis, and product purchase evaluation study. J Med Internet Res. 2024;26:e65440. PubMed 39509151
  7. PubChem. Retatrutide (CID 171390338): molecular formula C221H342N46O68, molecular weight 4731. National Library of Medicine, accessed November 20, 2026. pubchem.ncbi.nlm.nih.gov
  8. Whoriskey P. The "miracle drug" and the peptide craze breaking the FDA. Public Citizen Health Research Group, June 16, 2026. citizen.org
  9. Buzzi RM, Huber LC. Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ Case Rep. 2026;19(10):e276106. PubMed 42843917
  10. Branine N. Online-sourced retatrutide complicating impending diabetic ketoacidosis in a patient with type 1 diabetes and concurrent Shigella gastroenteritis. Cureus. 2026;18(8):e115260. PubMed 42669023

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo